ATE493977T1 - Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen - Google Patents

Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen

Info

Publication number
ATE493977T1
ATE493977T1 AT07117778T AT07117778T ATE493977T1 AT E493977 T1 ATE493977 T1 AT E493977T1 AT 07117778 T AT07117778 T AT 07117778T AT 07117778 T AT07117778 T AT 07117778T AT E493977 T1 ATE493977 T1 AT E493977T1
Authority
AT
Austria
Prior art keywords
treatment
inflammatory diseases
composition
psychotropic cannabinoids
prevention
Prior art date
Application number
AT07117778T
Other languages
English (en)
Inventor
Blanco Eduardo Munoz
Giovanni Appendino
Bernd L Fiebich
Giampaolo Grassi
Original Assignee
Vivacell Biotechnology Espana S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivacell Biotechnology Espana S L filed Critical Vivacell Biotechnology Espana S L
Application granted granted Critical
Publication of ATE493977T1 publication Critical patent/ATE493977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07117778T 2007-10-02 2007-10-02 Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen ATE493977T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07117778A EP2044935B1 (de) 2007-10-02 2007-10-02 Zusammensetzung mit nicht-psychotropen Cannabinoiden zur Behandlung von Entzündungserkrankungen

Publications (1)

Publication Number Publication Date
ATE493977T1 true ATE493977T1 (de) 2011-01-15

Family

ID=38969403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07117778T ATE493977T1 (de) 2007-10-02 2007-10-02 Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen

Country Status (8)

Country Link
US (1) US20100222437A1 (de)
EP (1) EP2044935B1 (de)
JP (1) JP2010540587A (de)
AT (1) ATE493977T1 (de)
CA (1) CA2701368A1 (de)
DE (1) DE602007011766D1 (de)
ES (1) ES2359168T3 (de)
WO (1) WO2009043836A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
EP2571385B1 (de) * 2010-05-21 2017-01-11 Hzat Llc. Verfahren zur herstellung eines tabakextrakts für elektronische rauchvorrichtungen
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
US8906429B1 (en) * 2013-12-11 2014-12-09 Jeffrey A. Kolsky Medical cannabis lozenges and compositions thereof
WO2016004121A1 (en) * 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
WO2016178713A1 (en) * 2015-05-02 2016-11-10 Flavocure Biotech Llc Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of cancers
US9687469B2 (en) 2014-11-26 2017-06-27 University Of Maryland, Baltimore Agent containing flavonoid derivatives for treating cancer and inflammation
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US10207198B2 (en) 2015-01-22 2019-02-19 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
UY36530A (es) * 2015-01-22 2016-08-31 Phytoplant Res S L Métodos para purificar cannabinoides, composiciones y kits de estos
US10155708B2 (en) 2015-01-22 2018-12-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
MX382296B (es) * 2015-05-27 2025-03-13 Cannabics Pharmaceuticals Inc Sistema y método para la detección de alto rendimiento de células cancerígenas.
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3664795B1 (de) 2017-08-09 2024-06-19 Cannibite BVBA Cannabis und derivate davon zur behandlung von schmerzen und entzündungen im zusammenhang mit zahnmark und knochenregeneration im zusammenhang mit kieferknochendefekten
US20200405685A1 (en) * 2017-12-08 2020-12-31 Biotech Institute, Llc High cannabigerol cannabis plants, methods of producing and methods of using them
EP3502692A1 (de) * 2017-12-20 2019-06-26 Aposcience AG Wirksamkeitstest für sekretom
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
CA3055225A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
BR112020020850A2 (pt) 2018-04-09 2021-01-19 Ellevet Sciences Extrato de cânhamo para tratamento da dor em animais
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
SG10201902000YA (en) 2019-03-06 2020-10-29 Nat Univ Singapore Isthmin 1 for treatment of lung inflammation
US20220242810A1 (en) * 2019-06-14 2022-08-04 Purisys Llc Crystalline cannabigerol
EP4076485A4 (de) * 2019-12-19 2024-03-27 Steven Rothstein Mit polyphenolischen verbindungen angereicherte extrakte und verwandte verfahren
US20220347071A1 (en) * 2021-04-28 2022-11-03 Demetrix, Inc. Use of cannabinoids in the treatment of oral inflammation and periodontal disease
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2023239415A1 (en) * 2022-06-08 2023-12-14 Angrow Company Limited Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US6403126B1 (en) * 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids

Also Published As

Publication number Publication date
DE602007011766D1 (de) 2011-02-17
ES2359168T3 (es) 2011-05-19
EP2044935A1 (de) 2009-04-08
JP2010540587A (ja) 2010-12-24
CA2701368A1 (en) 2009-04-09
EP2044935B1 (de) 2011-01-05
US20100222437A1 (en) 2010-09-02
WO2009043836A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
ATE493977T1 (de) Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen
CY1122076T1 (el) Φυτικα εκχυλισματα που περιεχουν κανναβινοειδες σαν νευρο-προστατευτικοι παραγοντες
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
UA108852C2 (ru) Применение одного или комбинации фито каннабиноидов для лечения эпилепсии
WO2010051277A8 (en) Process for the production of alpha-tocotrienol and derivatives
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
MX2010005114A (es) Uso de las soluciones de aceite de menta o de l-carvona para el tratamiento fungicida y/o antigerminacion de bulbos y/o tuberculos.
WO2008011363A3 (en) Quercetin-containing compositions
CR20110103A (es) Heteroarilos sustituidos
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
BRPI0715763A2 (pt) tratamento ou prevenÇço de cÂnceres superexpressando reg4 ou kiaa0101
BRPI0711889B8 (pt) método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina
ATE544804T1 (de) Teilaromatisches copolyamid und herstellungsverfahren dafür
GT200600327A (es) Ciclohexilaminoisoquinolona
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
CR20120281A (es) Composiciones repelentes y métodos genéticos para controlar huanglogbing en cítricos
EA201170567A1 (ru) Смесь силанов
ATE416629T1 (de) Antioxidative zusammensetzungen
TW200602341A (en) Processes and intermediates
WO2009126672A3 (en) 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides
WO2009092052A3 (en) Methods and compositions for treating polyps
ATE523543T1 (de) Alkylierte aminoproyliertes methylen-di- (cyclohexylamin) und verwendungen davon
ATE518828T1 (de) Ein-topf-verfahren zur herstellung von 3-(2,2,2- trimethylhydrazinium)propionat-dihydrat
NL2001953A1 (nl) Method for manufacture of escitalopram.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties